Cargando…
Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding
Lung cancer is currently one of the leading causes of the cancer-related deaths in the world. Erlotinib and Gefitinib are inhibitors of human epidermal growth factor receptor-1 and the epidermal growth factor receptor tyrosine kinase. The most common adverse events for erlotinib and gefitinib were m...
Autores principales: | Bai, Hongmei, Liu, Qing, Shi, Maowei, Zhang, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Professional Medical Publicaitons
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858952/ https://www.ncbi.nlm.nih.gov/pubmed/24353736 |
Ejemplares similares
-
Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013) -
Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011) -
Bleeding with gastrointestinal and ureteral ulcers after gefitinib treatment: a case report
por: Xiao, Jian, et al.
Publicado: (2021) -
Treatment with gefitinib after erlotinib-induced liver injury: a case report
por: Nakatomi, Katsumi, et al.
Publicado: (2011) -
Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)